MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

MDT

100.71

-0.28%↓

A

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

10

+1.94%↑

Search

Certara Inc

Slēgts

SektorsVeselības aprūpe

10.09 1

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.72

Max

10.14

Galvenie mērījumi

By Trading Economics

Ienākumi

3.5M

1.5M

Pārdošana

46K

105M

P/E

Sektora vidējais

135.857

89.037

Peļņas marža

1.458

Darbinieki

1,487

EBITDA

-6.5M

23M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+21.1% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 25. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-365M

1.5B

Iepriekšējā atvēršanas cena

9.09

Iepriekšējā slēgšanas cena

10.09

Ziņu noskaņojums

By Acuity

50%

50%

145 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Certara Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 25. janv. 23:49 UTC

Tirgus saruna

Oil Falls on Possible Technical Correction -- Market Talk

2026. g. 25. janv. 23:43 UTC

Tirgus saruna

Correction to Gold Rises Above $5000/oz Market Talk

2026. g. 25. janv. 23:43 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 25. janv. 23:43 UTC

Tirgus saruna

Nikkei May Fall After Yen's Sharp Rebound -- Market Talk

2026. g. 25. janv. 23:36 UTC

Tirgus saruna

Gold Rises Above $5,000/oz for First Time Amid Geopolitical Tensions -- Market Talk

2026. g. 25. janv. 19:30 UTC

Iegādes, apvienošanās, pārņemšana

Merck No Longer in Talks to Acquire Revolution Medicines, Sources Say -- WSJ

2026. g. 25. janv. 19:30 UTC

Iegādes, apvienošanās, pārņemšana

Companies Had Been Discussing Roughly $30B Deal -- WSJ

2026. g. 25. janv. 19:30 UTC

Iegādes, apvienošanās, pārņemšana

Merck No Longer in Talks to Buy Revolution Medicines -- WSJ

2026. g. 24. janv. 09:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 24. janv. 09:20 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 24. janv. 09:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 24. janv. 09:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 24. janv. 06:18 UTC

Iegādes, apvienošanās, pārņemšana

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

2026. g. 23. janv. 22:30 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. janv. 22:30 UTC

Tirgus saruna

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

2026. g. 23. janv. 22:03 UTC

Peļņas

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

2026. g. 23. janv. 21:52 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

2026. g. 23. janv. 21:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 23. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 23. janv. 21:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 23. janv. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 23. janv. 21:39 UTC

Peļņas

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

2026. g. 23. janv. 21:15 UTC

Iegādes, apvienošanās, pārņemšana

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

2026. g. 23. janv. 21:12 UTC

Peļņas

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

2026. g. 23. janv. 20:31 UTC

Peļņas

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

2026. g. 23. janv. 20:12 UTC

Tirgus saruna

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

2026. g. 23. janv. 20:07 UTC

Tirgus saruna

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

2026. g. 23. janv. 19:36 UTC

Tirgus saruna

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

2026. g. 23. janv. 19:30 UTC

Tirgus saruna
Peļņas

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

2026. g. 23. janv. 19:18 UTC

Tirgus saruna

Gold and Silver Step Up to More Records -- Market Talk

Salīdzinājums

Cenas izmaiņa

Certara Inc Prognoze

Cenas mērķis

By TipRanks

21.1% augšup

Prognoze 12 mēnešiem

Vidējais 12.11 USD  21.1%

Augstākais 16 USD

Zemākais 9 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Certara Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

7

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

11.27 / 12.79Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

145 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat